Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.…
Devyser Diagnostics AB (OSTO:DVYSR) (Q3 2026) Earnings Call Highlights: Strong Margins and ...
Devyser Diagnostics (STO: DVYSR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 111 employees.
The shares were at 60.00 SEK on 20 November 2026, down 45.0% over 52 weeks. Its 52-week range is 48.50 SEK to 120.00 SEK: the price is 50.0% below the high and 23.7% above the low.
At a market capitalisation of 1.01B SEK, it trades at 39.2 times trailing earnings and 98.4 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 54% for DVYSR.
Devyser Diagnostics reports return on equity of -2.4%, an operating margin of 11.5% and revenue up 5.9% year over year.
It holds more cash than debt, a net cash position of 44.70M SEK. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 102.09 SEK is 70.1% above the current price. The next earnings report is expected on 16 February 2027.